[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obstructive-sleep-apnea-of-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obstructive-sleep-apnea-of-adult":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,42,76,106,134,160,182,202,231,255,279,301,326,348,367,396,419,442],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100516753","clinical-trial-of-the-cryosa-system-for-the-treatment-of-obstructive-sleep-apnea-100516753",false,"NCT06008626","Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea","Multicenter Pilot Study of the Cryosa System for the Treatment of Obstructive Sleep Apnea","ARCTIC-3","Inclusion Criteria:\n\n1. To participate in this study, the subject must meet ALL of the following inclusion criteria:\n2. Age 22 - 70 years\n3. Not able to use, refuse to use or intolerant of Positive Airway Pressure (PAP) or Mandibular Advancement Device (MAD) if using, must be \\\u003C 4 hours per night, \\\u003C 5 days\u002Fweek.\n4. Failed, are not candidates for, or have refused other invasive procedures such as hypoglossal nerve stimulation or pharmacotherapy for the primary treatment of OSA such as Tirzepatide.\n5. BMI ≥30 or ≤ 40 kg\u002Fm2 at enrollment\n6. AHI ≥30 at enrollment based on in-lab polysomnography study OR AHI ≥ 15 and BMI of ≥ 30 at enrollment based on in-lab polysomnography study Is geographically stable and in close proximity to the site\n7. Able and willing to provide written consent to participate in the study\n\nExclusion Criteria:\n\n1. Contraindication to general anesthesia or in the opinion of the Investigator would not be able to tolerate the procedure, including intubation during the procedure or in response to an adverse event\n2. Actively taking ACEs\u002FARBs\n3. Actively undergoing immunotherapy (Allergy shots)\\*, or unwilling to washout of allergy shots at least 2 weeks prior to study procedure.\n\n   \\* Patients receiving immunotherapy may be eligible if they undergo a 2-week wash-out prior to the study procedure\n4. Severe uncontrolled asthma\n5. Severe maxillary mandibular insufficiency that in the opinion of the investigator thought to be the primary cause of OSA\n6. Obvious severe fixed upper airway obstructions (tumors, polyps, nasal obstruction)\n7. Previous surgery within 12 weeks of scheduled procedure performed on the soft tissue of the upper airway (e.g., uvula, soft palate, or tonsils).\n8. Oral cancer or non-healing oral wounds\n9. Prior sleep surgeries, including tongue base reduction, UPPP and hypoglossal nerve stimulation.\n10. History of radiation therapy to neck or upper respiratory tract\n11. Surgical resection for cancer or congenital malformations in the larynx, tongue, or throat (with exception of tonsillectomy and\u002For adenoidectomy)\n12. History presence of cold urticaria at the time of screening History of cryoglobulinemia\n13. History of allergy to glycerin\n14. History of hospitalization with mechanical ventilation due to COVID-19 per investigator discretion\n15. Resistant hypertension defined as a blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes taken at maximally tolerated doses\n16. Patients with diagnosed autoimmune disorders including thyroid disease, lupus, multiple myeloma, chronic lymphocytic leukemia\n17. Neuromuscular disease or other neurologic deficits (for example multiple sclerosis, muscular dystrophy, Parkinson's disease, transient ischemic attack, epilepsy or cerebrovascular accident)\n18. Diagnosis of any moderate to severe congestive obstructive pulmonary disease (COPD)\n19. Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism) History of angioedema of the airway\n20. Hereditary angioedema and other autoimmune disorders that could lead to acquired angioedema - confirmed with a compliment component C4 blood test \\\u003C13mg\u002FdL.\n21. Uncontrolled Diabetes (including Diabetes Mellitus \\[DM\\] or Insulin Dependent Diabetes Mellitus \\[IDDM\\]) with HbA1c \\>9.\n22. Currently receiving treatment for severe cardiac valvular dysfunction, NYHA Class III or IV heart failure, unstable angina or recent (\\\u003C 12 months) myocardial infarction or severe cardiac arrhythmias\n23. Subjects with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months\n24. Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 6 months\n25. History or current clinical evidence of TIA or stroke or muscular dysfunction\n26. Current smoker (≥ 1 pack\u002Fday)\n27. Presence of occupational shift work or anticipation of shift changes during the next 2 years\n28. Subject has sleep hygiene behavior that is likely to interfere with measurement outcomes during PSG and\u002For HSAT\n29. Known active substance use disorder\n30. Other severe sleep disorders that in the opinion of the investigator, confound functional assessments of sleepiness such as narcolepsy with cataplexy, severe insomnia\u002Finsomnia secondary to chronic pain, PTSD\n31. Patients taking any of the following medication that could affect study endpoints: benzodiazepines, Z-drugs (zolpidem and eszopiclone) opiates, antipsychotics (neuroleptics), phenothiazines, and prescription stimulants (including Sunosi, Provigil, and Nuvigil)\n32. Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject's ability to meet study requirements and ability to provide study consent\n33. Females who are pregnant or females of childbearing age with intention to become pregnant during the study period (≤ 3 months from treatment date)\n34. Any other reason the investigator deems subject is unfit for participation in the study\n35. Subject currently participating in other premarket investigational studies unless approved by Sponsor in writing","ALL","22 Years","70 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective, multicenter, non-randomized single-arm safety and performance study to collect data to evaluate the safety of the Cryosa procedure to treat obstructive sleep apnea (OSA) in patients with moderate to severe OSA. The study will also evaluate the chronic performance of the Cryosa system and collect clinical measures for therapy effectiveness that will be used to demonstrate safety and effectiveness in the next clinical study.",[28],"Obstructive Sleep Apnea of Adult","RECRUITING","2026-04-27",{"date":32,"type":33},"2026-04-30","ACTUAL",{"date":35,"type":33},"2023-09-12",{"date":37,"type":22},"2028-06-30",{"name":39,"class":40},"Cryosa, Inc.","INDUSTRY",9,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100305377","phase-1-cerebral-blood-flow-and-ventilatory-responses-during-sleep-in-normoxia-and-intermittent-hypoxia-100305377","NCT03255408","Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia","Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia","Inclusion Criteria:\n\n* Healthy adults\n* 18 - 45 years of age\n* Living in Calgary for the past one year\n* Have no medical condition or should not be taking any blood pressure medications.\n* The participant should not be lactose intolerant\n\nExclusion Criteria:\n\n* Cerebrovascular, cardio-respiratory, renal and metabolic diseases\n* Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease\n* Pregnancy, obese and sleep-disordered breathing\n* Drug allergies to non-steroidal anti-inflammatories\n* Currently smoking",true,"18 Years","45 Years",{"count":53,"type":22},12,[55,56],"PHASE1","PHASE2","A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).",[28,59,60,61,62,63,64,65],"Hypoxia, Brain","Sleep Apnea","Sleep Disorder","Stroke","Blood Pressure","Endothelial Dysfunction","Oxidative Stress",{"date":67,"type":33},"2026-05-01",{"date":69,"type":33},"2023-01-01",{"date":71,"type":22},"2027-12-30",{"name":73,"class":74},"University of Calgary","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":50,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100323149","continuous-positive-airway-pressure-cpap-for-sleep-apnea-in-pregnancy-100323149","NCT03487185","Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy","A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy","SLEEP","Inclusion Criteria\n\n1. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or therapeutically, is not eligible unless the reduction occurred before 14 weeks project gestational age.\n2. Gestational age at randomization between 14 weeks 0 days and 21 weeks 6 days based on clinical information and evaluation of the earliest ultrasound.\n3. Diagnosis with mild to moderate OSA as defined by an AHI score ≥ 5 and \\\u003C30.\n\nExclusion Criteria\n\n1. Previously prescribed, current or planned therapy for sleep apnea.\n2. Age \\\u003C 18 years, because the rate of sleep apnea in this population is extremely low.\n3. Inability to sleep in a stable place with access to the CPAP machine at least 5 nights per week.\n4. Asthma requiring systemic steroid therapy for more than 14 days within the past 6 months because this population is expected to be unresponsive to CPAP therapy.\n5. Current use of prescribed sleeping pills for insomnia.\n6. Chronic medical conditions requiring oxygen supplementation (e.g. pulmonary fibrosis, pulmonary hypertension, cystic fibrosis) because this population is expected to be unresponsive to CPAP therapy.\n7. Chronic renal disease with serum creatinine \\>1.3 mg\u002FdL because the primary outcome would be pre-determined.\n8. Antiphospholipid antibody syndrome, because it would compromise the primary outcome diagnosis.\n9. History of medical complications such as:\n\n   1. Active liver disease (acute hepatitis, chronic active hepatitis, persistently abnormal liver enzymes)\n   2. Thrombocytopenia with platelet count \\\u003C100,000 because of the difficulty in assessing the primary outcome.\n10. Active vaginal bleeding (more than spotting) at the time of randomization.\n11. Known chromosomal, genetic, major malformations or fetal demise, or planned termination of pregnancy because inclusion would compromise evaluation of secondary neonatal outcomes.\n12. Known major uterine malformations associated with adverse pregnancy outcomes.\n13. Current use of opiates (heroin, methadone, or other daily opioid use) due to inaccuracy of the home sleep test and inefficiency of CPAP.\n14. Active drug use, alcohol use, or unstable psychiatric condition.\n15. Participation in another interventional study that influences preeclampsia, hypertensive disorders of pregnancy, or GDM.\n16. Prenatal care or delivery planned at a non-network center where access to the complete electronic medical record will not be available to research staff.\n17. Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.","FEMALE",{"count":86,"type":22},1500,[25],"A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy.",[28,90,91],"Preeclampsia","Obstetrical Complications",[93,94,95],"CPAP","Apnea","pregnancy","2026-04-03",{"date":98,"type":33},"2026-04-06",{"date":100,"type":33},"2018-08-03",{"date":102,"type":22},"2026-12-31",{"name":104,"class":74},"The George Washington University Biostatistics Center",14,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":75},"100545329","phase-4-melatonins-effect-on-nighttime-blood-pressure-and-sleep-in-osa-patients-mebp-osa-100545329","NCT06380491","Melatonin's Effect on Nighttime Blood Pressure and Sleep in OSA Patients (MEBP-OSA)","Impact of Melatonin Treatment on Blood Pressure Circadian Rhythm, Sleep and Metabolic Variables.","MEBP-OSA","Inclusion Criteria:\n\n* Polisomnographic diagnosis of Obstructive Sleep Apnea\n* Non-dipping blood pressure on Ambulatory blood pressure monitoring (ABPM):\n\nExclusion Criteria:\n\n* Use of sleep or psychiatric medication\n* Use of Positive Airway Pressure (CPAP or Bipap)\n* Neurologic or psychiatric disorder","60 Years",{"count":116,"type":22},50,[118],"PHASE4","The goal of this clinical trial is to learn if melatonin works to treat comorbid insomnia in adults with OSA and nocturnal non-dipping blood pressure pattern.\n\nThe main question it aims to answer is:\n\nDoes melatonin maintain sleep during night and recover the dipping blood pressure pattern?",[28],[122,123,124],"Circadian Blood Pressure Rhythm","Obstructive sleep apnea","Melatonin","2026-03-30",{"date":127,"type":33},"2026-04-01",{"date":129,"type":33},"2023-06-22",{"date":131,"type":22},"2028-01-22",{"name":133,"class":74},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100549203","osa-risk-level-in-dental-patients-and-correlation-with-complications-after-general-anesthesia-100549203","NCT06430957","OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia","Evaluation of OSA Risk Levels in the Preoperative Period of Adult Patients With Planned Dental Procedures Under Anesthesia and Correlation With Postoperative Complications; A Multicenter Study","Inclusion Criteria:\n\n* Patients between 18-80 years of age who apply to the anesthesia clinic for dental procedures planned to be performed under general anesthesia\n* Patients without a previous diagnosis of OSA\n\nExclusion Criteria:\n\n* Individuals who do not want to participate in the study\n* Patients previously diagnosed with OSA\n* Necessity of emergency surgery","80 Years",{"count":143,"type":22},240,"OBSERVATIONAL","Obstructive sleep apnea (OSA) is a sleep-related respiratory dysfunction. The prevalence of OSA is increasing with the increasing rates of obesity and elderly population worldwide. Perioperative anesthesia management should be adjusted to improve patient safety in patients with OSA. In OSA patients, positive pressure ventilation support may be required in the preoperative period, various ventilation strategies may be required in the intraoperative period, different pharmacologic agents may need to be avoided, and intensive care unit follow-up or noninvasive ventilation support may be required in the postoperative period. However, it is reported that a significant percentage of OSA patients remain undiagnosed. ASA (American Society of Anesthesiologists) has reported the criteria that should be questioned in order to determine the risk of patients in terms of OSA and to initiate the diagnostic process in risky patients and to make appropriate anesthesiologic arrangements in the perioperative period. In addition, the STOP-BANG assessment scale, which is widely used all over the world in OSA risk assessment, is also used in OSA risk assessment. It is thought that dental caries and extraction needs may be higher in OSA patients, especially since open-mouth sleeping accompanies the situation. In this respect, it is also important for patients to be diagnosed with OSA as it may prevent dental damage due to open-mouth sleeping in the future. Identifying patients at risk for OSA and directing them to the diagnostic process is very important for patient safety. Within the scope of the study, the criteria recommended by ASA and STOP-BANG score will be evaluated and recorded. Risk stratification in terms of STOP-BANG questionnaire and ASA criteria will be done separately for each patient and for each classification method. Patients at high risk will be consulted to the relevant medical department in the preoperative period for further investigation and treatment. In addition, it is aimed to correlate the risk levels determined in the study with postoperative respiratory complications and recovery time.",[147,148,149,28],"Obstructive Sleep Apnea Risk Management","Postoperative Complications","Dental Caries Under General Anesthesia","2026-03-19",{"date":152,"type":33},"2026-03-20",{"date":154,"type":33},"2024-06-28",{"date":156,"type":22},"2026-08",{"name":158,"class":74},"Kırıkkale University",2,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":75},"100461469","phase-1-vascular-endothelial-dysfunction-in-sleep-apnea-100461469","NCT05289063","Vascular Endothelial Dysfunction in Sleep Apnea","Inclusion Criteria:\n\n* Aged ≥18 years\n* Newly diagnosed with obstructive sleep apnea (OSA) who were never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) ≥5 events\u002Fhour of sleep.\n\nExclusion Criteria:\n\n* A history of coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain\u002Ffatigue, smoking within the past 5 years\n* Regular use of any medications",{"count":167,"type":22},110,[55],"This double-blind placebo-controlled parallel group randomized study design will be used to test whether 4 weeks of atorvastatin 10 mg daily reduces levels of inflammatory markers in OSA patients treated with CPAP (standard of care). The purpose of this study is to investigate: 1) whether statins reduce endothelial inflammation and pro-thrombotic conditions in OSA, including in patients adherent to CPAP (Aim 1); and 2) whether statins reduce endothelial inflammation and pro-thrombotic conditions by improving endothelial cholesterol metabolism and trafficking in OSA (Aim 2).",[28],[93,172],"Atorvastatin","2026-02-11",{"date":175,"type":33},"2026-02-13",{"date":177,"type":33},"2022-10-03",{"date":179,"type":22},"2027-02-28",{"name":181,"class":74},"Columbia University",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":114,"enrollmentInfo":188,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":75},"100309360","a-cross-sectional-study-examining-adipose-tissue-in-obstructive-sleep-apnea-100309360","NCT03307330","A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea","Inclusion Criteria\n\n* BMI ≤40 kg\u002Fm2\n* Not a current smoker or tobacco user\n* Individuals with treated hypertension, prehypertension, and dyslipidemia will be allowed to participate in the study\n* On no prescription medications other than those medications used to treat asthma, seasonal or environmental allergies (such as Cetirizine, Fexofenadine, Desloratadine, Loratadine, etc), depression, acid reflux (such as antacids or proton pump inhibitors), topical skin treatment medications or shampoos, contraceptive pills, or intrauterine devices. Other medications may be allowed at the discretion of the study staff.\n* Not pregnant or breast feeding and not intending to become pregnant or breast feed\n* Ability to provide written informed consent\n* If a subject is on aspirin or any other anti-inflammatory medication but free of known vascular disease and depending on the indication, the study doctor may ask the subject to suspend aspirin or anti-inflammatory therapy for 7 days prior to participation in the study. In the event that the subject does not stop the aspirin or other anti-inflammatory medication, they will not be able to participate in the study because of the risk of bleeding during the fat biopsy.\n\nExclusion Criteria\n\n* Vulnerable study population will be excluded\n* Presence of chronic kidney disease (creatinine \\>2.5 mg\u002FdL) and\u002For active cancers\n* Pregnancy\n* Anemic (hemoglobin \\\u003C12 g\u002FdL for men and \\\u003C11 g\u002FdL for women)\n* Smoking\n* Use of chronic medications (statins, anti-inflammatory drugs, angiotensin II receptor blockers (ARBs) and\u002For angiotensin-converting enzyme (ACE) inhibitors)\n* Blood or plasma donation during the past 2 months",{"count":189,"type":22},120,"Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.",[28],[193,194],"Obstructive Sleep Apnea","Adipose Tissue",{"date":175,"type":33},{"date":197,"type":33},"2018-01-08",{"date":199,"type":22},"2029-12",{"name":201,"class":74},"Mayo Clinic",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":75},"100526264","phase-4-impact-glp-1-agonists-following-bariatric-100526264","NCT06132477","Impact GLP-1 Agonists Following Bariatric","Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric","Inclusion Criteria:\n\n1. Greater than 18 years of age\n2. Participation in care by one of the surgeons at MU Health Care\n3. Undergoing surgical weight loss through the Weight Management and Metabolic Center\n4. Body mass index of 30-80 kg\u002Fm2\n5. Meet insurance criteria, as set forth by the patient's insurance policy, to qualify for coverage for weight loss surgery or as a self-pay patient for the weight loss procedure\n6. Planned laparoscopic Roux-en-Y gastric bypass, sleeve gastrectomy, revisional weight loss surgery, or duodenal switch or modification of. If patients are not willing to be randomized they will not be enrolled as randomized but can still participate having samples collected.\n7. Willingness to have blood collected before and after surgical procedure at defined points or at minimum have clinical data collected.\n8. Willingness to have clinical data entered into a prospective database\n9. Additional specimens collected as stated in the protocol will be offered but collection not mandated.\n\n5\\. Taking a GLP-1 agonist as part of their routine medical care apart from any planned surgical procedure. The current standard of care regarding continuation or discontinuation of GLP-1 agonists has not been established and is at the discretion of members of the patient's medical team but to be included the patient and medical care team must be willing to continue or discontinue the GLP-1 agonist after surgery depending on the randomized group.\n\nExclusion Criteria:\n\n1. Pregnant patient\n2. Desire to not participate\n3. Age less than 18\n4. Patient fails to fulfill insurance mandated criteria and is not interested in paying cash for their procedure\n5. Not taking a GLP-1 agonist as part of standard medical care\n6. Unwilling to follow-up at required postoperative visits\n7. Unwilling to stop GLP-1 agonist if randomized into group to stop GLP-1 agonist or unwilling to continue the GLP-1 agonist if randomized into that respective group. If chooses to continue or discontinue the medication apart from randomization the patient can still participate as a non-randomized participant",{"count":210,"type":22},150,[118],"Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control. Bariatric surgical procedures have been shown to be effective in treating obesity as well as superior to best medical therapy for treatment of diabetes not just through restriction of calories but also through a positive impact in modifications of gut hormones, changes in circulating bile acids, modifications in the gut microflora as well as other undefined mechanisms. The combined benefits of GLP1-RAs with bariatric surgery have only been studied to a limited effect. In this randomized trial, the effects of continuation or discontinuation of GLP1-RA therapy in patients undergoing bariatric surgery will be determined. We will compare changes in weight, metabolic determinants including circulating bile acids and gut microbiome, psychological determinants of eating behavior, and adverse side effects in patients who continue vs discontinue therapy. Given differences in metabolic and clinical outcomes in patients undergoing vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB), both surgical groups will be examined. The study will be conducted at a high volume bariatric surgical program where patients will undergo randomization at the time of final clinic visit prior to surgery to continue or discontinue GLP1-RA. It is hypothesized that participants who continue GLP1-RA therapy after bariatric surgery will lose more weight with improved blood glucose control than those who discontinue therapy. Furthermore, changes in gut microbiome and circulating bile acids, known determinants of metabolic health, will be modified to a differential extent in those who are on GLP1-RAs vs those where GLP1-RAs are discontinued. Understanding the role these medications play in not only clinical outcomes after metabolic surgery but potential metabolic mechanisms by which surgery improves patient's metabolic health could help people with obesity and type 2 diabetes make informed decisions about their treatment options as well as advise providers on the continuation of these medications in the perioperative and postoperative period.",[214,215,216,217,28],"Morbid Obesity","Metabolic Syndrome","Diabetes Mellitus","Hypertension",[219,214,220,221,216,217,193],"glp-1 agonist","Bariatric Surgery","Metabolic syndrome","2026-01-21",{"date":224,"type":33},"2026-01-22",{"date":226,"type":33},"2024-02-01",{"date":228,"type":22},"2030-07",{"name":230,"class":74},"University of Missouri-Columbia",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":75},"100525118","effect-of-inspiratory-muscle-training-in-obstructive-sleep-apnea-syndrome-100525118","NCT06117579","Effect of Inspiratory Muscle Training in Obstructive Sleep Apnea Syndrome.","Effect of Inspiratory Muscle Training on Daytime Sleepiness in Obstructive Sleep Apnea Syndrome : Prospective Randomized Controlled Trial","NOCTURNE","Inclusion Criteria:\n\n* patients over 18 years of age with\n* OSA with an Apnea Hypopnea Index ≥ 5 requiring CPAP\n\nExclusion Criteria:\n\n* Sleep apnea of neurological or mixed origin,\n* Contraindication to or refusal of CPAP,\n* Cognitive disorders,\n* protected persons (under guardianship or curatorship),\n* persons under court protection,\n* persons not affiliated to a social security scheme\n* pregnant or breast-feeding women.",{"count":240,"type":22},58,[25],"Sleep apnea-hypopnea syndrome is a sleep-related respiratory disorder characterized by partial or total interruptions in breathing during sleep. The majority of syndromes involve an obstructive mechanism (OSA), caused by a reduction in the caliber of the upper airway (UA), most often associated with hypotonia of the surrounding muscles, preventing air from entering the UA during inspiration. The clinical consequences of this syndrome are excessive fatigue and daytime sleepiness, which have a negative impact on the quality of life of patients.\n\nDespite the positive results on apnea-hypopnea index and daytime sleepiness of continuous positive airway pressure (today's reference treatment), its 3-year compliance rate (i.e 59.9% according to a study by Abdelghani et al points to the need to develop other associated therapies.\n\nSeveral studies have demonstrated the efficacy of physiotherapy, such as physical activity and oro-pharyngeal muscle strengthening, notably on the apnea-hypopnea index and daytime sleepiness measured by the Epworth scale.\n\nFew studies have investigated the effect of inspiratory muscle training (IMT), even though the use of the inspiratory musculature (i.e. the diaphragm) is a means of supplementing the peri-pharyngeal muscles, as it helps to maintain the permeability of the upper airways. Inspiratory muscle training (IMT) could therefore be considered as part of the physiotherapeutic management of the OSA. The heterogeneity of current results concerning IMT in OSA , but above all the lack of evidence that it is dangerous, means that new clinical studies could be carried out in an attempt to demonstrate its efficacy. Our research hypothesis is therefore as follows: Implementing an inspiratory muscle strengthening protocol in patients suffering from OSA can reduce daytime sleepiness.",[28],[193,245],"Inspiratory muscle training","2025-12-22",{"date":248,"type":33},"2025-12-30",{"date":250,"type":33},"2024-06-26",{"date":252,"type":22},"2027-01-25",{"name":254,"class":74},"Centre Hospitalier Régional d'Orléans",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":265,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":75},"100571460","cardiometabolic-risk-effects-of-short-term-cessation-of-neurostimulation-therapy-100571460","NCT06720545","Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy","Cardiometabolic Risk Effects of Short-term Cessation of Effective Neurostimulation Therapy in OSA","CRESCENT","Inclusion Criteria:\n\n* English-speaking adults (18+ years) who have met surgical efficacy criteria with HGNS, as defined by at least a 50% reduction in apnea-hypopnea index (AHI) to \\\u003C20 (with hypopneas defined by 4% oxyhemoglobin desaturations)\n* Have been using HGNS therapy for at least 3 months and used HGNS for \\>20 hours\u002Fweek during the past 4 weeks\n* Were not using any OSA therapy for at least one month prior to HGNS activation or have had a one-month period of untreated OSA after HGNS activation\n\nExclusion Criteria:\n\n* Chronic use of opiate medications, illicit drugs, or alcohol dependency\n* Women who are pregnant or planning to become pregnant\n* Shift workers, heavy machinery operators, or commercial drivers\n* History of severe excessive daytime sleepiness (Epworth Sleepiness Scale score \\>16 at time of screening or prior to HGNS), motor vehicle accidents or near-miss incidents due to drowsy driving within the year prior to enrollment\n* Significant cardiopulmonary (such as home oxygen requirement), liver, renal, or oncologic disease; neurodegenerative disease; active or recent history of an eating disorder (within the last 5 years)\n* Inability to provide informed consent",{"count":264,"type":22},60,[25],"Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea.\n\nThe study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea (OSA).",[193,28],[269,270],"hypoglossal nerve stimulation","inspire","2025-07-05",{"date":273,"type":33},"2025-07-10",{"date":275,"type":33},"2025-01-05",{"date":277,"type":22},"2028-01",{"name":181,"class":74},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":17,"minAge":286,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":75},"100496084","comprehensive-respiratory-training-exercise-program-in-obstructive-sleep-apnea-100496084","NCT05739617","Comprehensive Respiratory Training Exercise Program in Obstructive Sleep Apnea","Combining Sonography to Explore the Therapeutic Effect and Mechanism of a Comprehensive Respiratory Training Exercise Program on Cardiorespiratory Endurance and Airway Muscle Function in Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Newly diagnosed with OSA (AHI≥ 5 events per hour)\n* Age between 20 to 65 years old\n* BMI of 18-30 kg.m-2\n\nExclusion Criteria: Diagnosed with any of the following diseases below:\n\n* Central or mixed types of sleep apnea\n* Neuromuscular disease\n* Severe cardiovascular disease\n* Active psychiatric disease\n* Head or neck disease or cancer\n* Structural abnormalities over the upper respiratory airway\n* Performed any operation or treatment over the neck before\n* Pregnancy","20 Years","65 Years",{"count":210,"type":22},[25],"Obstructive sleep apnea (OSA) is a multi-factorial sleep disorder. Complete collapse or partial collapse in the airway increases the risk of developing cardiovascular and kidney-related disease in OSA patients. Resulting in an increase in medical expenses and workload for the healthcare worker. Multilevel of upper airway muscles especially the genioglossus muscle showed to contribute to airway obstruction as it fatigues easily. The endurance level of OSA patients was shown to be significantly lower. Therefore, the goal of this experimental study is to assess the feasibility and effectiveness of a comprehensive respiratory training exercise program on cardiorespiratory endurance, airway muscle function, and sleep parameters in patients with obstructive sleep apnea (OSA). Aside from exploring the therapeutic effect, the results of the study will be used to explore the mechanism of the treatment in relation to the changes in the OSA severity.",[28],"2025-06-15",{"date":294,"type":33},"2025-06-18",{"date":296,"type":33},"2023-03-01",{"date":298,"type":22},"2026-07-16",{"name":300,"class":74},"National Cheng-Kung University Hospital",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":49,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":315,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100511415","an-extension-study-to-assess-the-long-term-safety-of-the-genio-system-100511415","NCT05939141","An Extension Study to Assess the Long-term Safety of the Genio® System","A Prospective, Open-label, Multicentric Extension Study to Assess the Long-term Safety of the Genio® System in Study Subjects Who Have Been Implanted With the Genio® Implantable Stimulator (IS) for the Treatment of OSA in Adult Patients.","OLE","Inclusion Criteria:\n\n* Subject voluntarily signed an Informed Consent Form\n* Subject is currently implanted with a Genio® Implantable Stimulator (IS), with therapy active or inactive, and was included in and subsequently exited a Nyxoah sponsored clinical investigation (either by study completion or withdrawal). These studies include, but are not limited to BLAST OSA (CL-GEN-001203), BETTER SLEEP (CL-GEN-001908), DREAM (CL-GEN-002033) or, subject is currently implanted with a Genio® Implantable Stimulator (IS) and accessing therapy via the TGA special access scheme (SAS).\n\nExclusion Criteria:\n\n* None",{"count":310,"type":22},39,"The objective of this study is to assess the long-term safety of the Genio® system in adult OSA patients with and without complete concentric collapse of the soft palate who have successfully been implanted with the Genio IS in a Nyxoah sponsored Clinical Investigation.\n\n(Serious) Adverse Device Effects and Device Deficiencies in subjects previously implanted with a Nyxoah Genio implantable stimulator (IS) and having the IS still in-situ (with therapy activated or deactivated) will be collected.\n\nThe main question it aims to answer is: what is the long term safety profile of the Genio System?\n\nParticipants will be asked to refer back to the site per standard of care and report on any (Serious) Adverse Device Effects and Device Deficiencies that may have occurred.",[28],[314],"OSA HGNS Hypoglossal Nerve Stimulation","NOT_YET_RECRUITING","2025-06-03",{"date":318,"type":33},"2025-06-04",{"date":320,"type":22},"2025-11",{"date":322,"type":22},"2029-07-17",{"name":324,"class":40},"Nyxoah S.A.",7,{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":346,"locationsCount":75},"100576968","smartwatch-based-ai-model-for-osa-prediction-swosa-100576968","NCT06792188","Smartwatch-Based AI Model for OSA Prediction (SWOSA)","Smartwatch-Based Artificial Intelligence Model for Obstructive Sleep Apnea Prediction","Inclusion Criteria:\n\n* Men and women aged 22 to 85 years who visited Seoul National University Hospital with suspected sleep apnea due to symptoms such as snoring, apnea, or excessive daytime sleepiness.\n\nExclusion Criteria:\n\n* Patients previously diagnosed with sleep apnea who are currently undergoing treatment (e.g., positive airway pressure \\[PAP\\] therapy, mechanical ventilation, oral appliances, or surgery).\n* Patients with neuromuscular diseases or a history of chronic opioid medication use.\n* Patients with severe insomnia that is not controlled by medication.\n* Patients receiving supplemental oxygen therapy due to underlying conditions such as heart failure, chronic obstructive pulmonary disease, interstitial lung disease, hypoventilation syndrome, or stroke, or whose baseline oxygen saturation is less than 90%.\n* Patients with implanted cardiac pacemakers, defibrillators, or other electronic devices.\n* Patients inexperienced in using smartphones, apps, or smartwatches.\n* Pregnant women.\n* Patients unable or unwilling to provide written informed consent.","85 Years",{"count":335,"type":22},147,"This study aims to develop an artificial intelligence (AI) model for more accurately diagnosing obstructive sleep apnea (OSA) by collecting blood oxygen saturation and other health information during sleep using a smartwatch.\n\nOSA is common but often underdiagnosed, and the gold-standard diagnostic test, polysomnography, is costly and time-consuming. Smartwatches can provide a variety of health data, such as sleep patterns, blood oxygen saturation, and heart rate, which can help detect key symptoms and signs of OSA.\n\nBy developing an AI model that uses smartwatch data to screen for OSA, this study seeks to offer a cost-effective and accessible diagnostic method, ultimately contributing to the early detection and improved treatment rates of OSA.",[28,338,339],"Screening","Smart Watch","2025-05-12",{"date":342,"type":33},"2025-05-15",{"date":344,"type":33},"2025-02-03",{"date":102,"type":22},{"name":347,"class":74},"Seoul National University Hospital",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":286,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":366,"locationsCount":75},"100555491","developing-a-treatment-clustering-system-for-obstructive-sleep-apnea-using-polysomnographic-physiological-signals-100555491","NCT06512779","Developing a Treatment Clustering System for Obstructive Sleep Apnea Using Polysomnographic Physiological Signals","Inclusion Criteria:\n\n* OSA patients\n* Aged over 20 years\n\nExclusion Criteria:\n\n* BMI≧ 32\n* Central or mixed types of sleep apnea\n* A history of malignancy or infection of the head and neck region and laryngeal trauma\n* Craniofacial malformation\n* Stroke\n* Neuromuscular disease\n* Severe cardiovascular disease\n* Active psychiatric disease\n* Structural abnormalities over the upper respiratory airway\n* Performed any operation or treatment over the neck before\n* Pregnancy",{"count":210,"type":22},[25],"Obstructive sleep apnea syndrome (OSA) is marked by repeated upper airway obstructions during sleep, affecting approximately 14% of men and 5% of women aged 30-70 years.\n\nHowever, precise clinical prediction tools for selecting optimal treatment strategies are lacking. This study aims to develop an automated treatment clustering system using artificial intelligence to classify patients based on etiology into (i) anatomical factors, (ii) reduced muscle responsiveness, and (iii) other non-anatomical factors. This system will analyze physiological sleep assessments, such as electromyography (EMG) and pneumotachographs, from a retrospective polysomnography (PSG) database. Cross-validation will be conducted on new OSA patients undergoing various management strategies, including surgical intervention, CPAP therapy, and oropharyngeal training (delivered face-to-face or via telerehabilitation). This system aims to enhance clinicians' ability to predict treatment success rates and improve patient outcomes.",[28],[193,359],"Treatment Clustering System","2024-08-04",{"date":362,"type":33},"2024-08-06",{"date":364,"type":33},"2024-07-30",{"date":67,"type":22},{"name":300,"class":74},{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":49,"sex":17,"minAge":374,"maxAge":19,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":383,"overallStatus":315,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":75},"100474378","obstructive-sleep-apnea-treatment-in-serious-mental-illness-100474378","NCT05457127","Obstructive Sleep Apnea Treatment in Serious Mental Illness","Obstructive Sleep Apnea Treatment in People Aging With Serious Mental Illness","Inclusion Criteria:\n\nControl participants:\n\n* lifetime absence of major psychiatric illness\n* 40 to 70 years old\n* be at risk for or have a diagnosis of obstructive sleep apnea\n\nFor participants with serious mental illness:\n\n* diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder\n* must not be conservatized\n* 40 - 70 years old\n* be at risk or have a diagnosis of obstructive sleep apnea.\n\nExclusion Criteria:\n\n* DSM-IV-TR diagnosis of active alcohol or other substance abuse or dependence in the 3 months preceding enrollment. This will be self-report.\n* Diagnosis of dementia, mental retardation, or other neurological or medical conditions known to affect neurophysiologic or neurocognitive functioning, or autoimmune disease\n* Other major DSM-IV-TR Axis I Disorder\n* Medical problems that interfere with a participant's ability to complete the assessments\n* Plans to move out of the San Diego county area within the following 6 months\n* Diagnosis of OSA and currently receiving APAP, CPAP, or any treatment from a physician.","40 Years",{"count":376,"type":22},300,[25],"Serious mental illnesses (SMI) like schizophrenia and bipolar disorder are two of the most disabling and costly chronic illnesses worldwide. A high proportion of adults with schizophrenia and bipolar disorder have sleep disorders, like obstructive sleep apnea (OSA), but tend to be underdiagnosed and undertreated compared to the general population. This study aims to examine feasibility, acceptance, and impact of OSA treatment and how it affects cognitive function in people with SMI.",[380,381,382,28],"Schizoaffective Disorder","Schizophrenia","Bipolar Disorder",[384,385,386],"Serious mental illness","aging","positive airway pressure","2024-07-08",{"date":389,"type":33},"2024-07-10",{"date":391,"type":22},"2025-01-01",{"date":393,"type":22},"2026-11",{"name":395,"class":74},"University of California, San Diego",{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":287,"enrollmentInfo":402,"targetDuration":404,"studyType":144,"phases":4,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":416,"locationsCount":75},"100550495","changes-in-difficult-airway-markers-after-surgery-for-obstructive-sleep-apnoea-syndrome-100550495","NCT06447818","Changes in Difficult Airway Markers After Surgery for Obstructive Sleep Apnoea Syndrome","Inclusion Criteria:\n\n* Age between 18-65\n* American society of assosication score (ASA) :1-3\n* To undergo Obstructive sleep apnea surgery (OSAS)\n\nExclusion Criteria:\n\n* Verbal and written consent cannot be obtained",{"count":403,"type":22},42,"1 Year","This study investigates the changes in difficult airway markers at 6 months post operatively in patients undergoing obstructive sleep apnoea surgery",[28,407],"Difficult or Failed Intubation",[409],"Obstructive sleep apnea surgery, Difficult airway markers","2024-06-03",{"date":412,"type":33},"2024-06-07",{"date":414,"type":33},"2024-05-15",{"date":342,"type":22},{"name":417,"class":418},"Kocaeli City Hospital","OTHER_GOV",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":17,"minAge":286,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":431,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":75},"100524047","efficacy-of-oropharyngeal-exercises-for-patients-with-obstructive-sleep-apnea-using-mandibular-advancement-device-100524047","NCT06103630","Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device","Efficacy of Oropharyngeal Exercises for Patients With Residual Obstructive Sleep Apnea Using Mandibular Advancement Device","Inclusion Criteria:\n\n* OSA patients\n* Aged over 20 years\n* Wearing MAD (The amount of MAD is at least 50% of the maximum amount that the patient can achieve.)\n\nExclusion Criteria:\n\n* Body Mass Index (BMI) ≧ 35\n* Pregnancy\n* Severe obstructive or restrictive lung disease\n* Exercise with high-risk cardiovascular disease\n* History of central or peripheral neurological disease resulting in an inability to perform exercise prescriptions\n* Musculoskeletal or psychological disorders that prevent the performance of exercise prescriptions\n* Chronic illnesses that are ongoing or not yet controlled",{"count":427,"type":22},20,[25],"Oropharyngeal muscle training has emerged as a novel adjunctive treatment approach, involving training of the swallowing muscle group and tongue muscles to prevent tongue collapse, reduce tongue base volume during sleep, and strengthen muscle tension.\n\nTherefore, the objective is to assess changes in oropharyngeal muscle strength, ultrasonographic tongue morphology, severity of sleep related breathing interruptions, clinical symptoms, and correlations among these factors. Oropharyngeal muscle training for patients with residual OSA using MAD can significantly 1. increase muscle strength and endurance. 2. reduce the severity of sleep-related breathing interruptions. 3. decrease clinical symptoms. 4. improve tongue morphology.",[28],[193,432,433],"Mandibular Advancement Device therapy","Oropharyngeal muscle training","2024-03-20",{"date":436,"type":33},"2024-03-21",{"date":438,"type":33},"2023-11-02",{"date":440,"type":22},"2027-12-31",{"name":300,"class":74},{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":19,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":75},"100537843","management-of-obstructive-sleep-apnea-syndrome-by-expansion-palatoplasty-100537843","NCT06283095","Management of Obstructive Sleep Apnea Syndrome by Expansion Palatoplasty","Inclusion Criteria:\n\n* Adult patients.\n* Body mass index \\\u003C 30 kg\u002Fm2 (weight \u002Fheight in m2)\n* Mild to moderate OSAS\n* Sagittal collapse of the lateral pharyngeal walls proved by Drug induced sleep endoscopy (DISE).\n\nExclusion Criteria:\n\n* • Refusing enrollment into the study.\n\n  * Pregnant women.\n  * Refusing the surgery\n  * Contraindication to anaesthesia\n  * Patients with multilevel of obstruction.\n  * Serious psychiatric, neurological and cardiopulmonary (COPD or corpulmonale) diseases.\n  * Uncorrected hypothyroidism.\n  * Severe OSAS.\n  * Craniofacial anamolies.\n  * Central\\& mixed apnea\n  * Morbid obesity.",{"count":449,"type":22},30,[25],"The study will be conducted to evaluate the outcome of expansion palatoplasty in management of OSAS.",[28],"2024-02-21",{"date":455,"type":33},"2024-02-28",{"date":457,"type":33},"2023-11-01",{"date":459,"type":22},"2026-11-01",{"name":461,"class":74},"ET Zarief"]